ZAGNI, Irene
 Distribuzione geografica
Continente #
NA - Nord America 914
EU - Europa 609
AS - Asia 227
OC - Oceania 2
SA - Sud America 2
Totale 1.754
Nazione #
US - Stati Uniti d'America 914
GB - Regno Unito 228
CN - Cina 201
SE - Svezia 78
IE - Irlanda 77
FR - Francia 67
DE - Germania 57
FI - Finlandia 40
IT - Italia 28
SG - Singapore 19
UA - Ucraina 15
RU - Federazione Russa 10
RO - Romania 3
AT - Austria 2
IN - India 2
NL - Olanda 2
TR - Turchia 2
AU - Australia 1
BG - Bulgaria 1
BR - Brasile 1
CL - Cile 1
IR - Iran 1
JP - Giappone 1
KR - Corea 1
NZ - Nuova Zelanda 1
PL - Polonia 1
Totale 1.754
Città #
Southend 197
Chandler 184
Jacksonville 182
Woodbridge 95
Houston 80
Dublin 77
Ashburn 60
Ann Arbor 49
Nanjing 30
Wilmington 29
Jinan 27
New York 27
Lawrence 23
Princeton 23
Shenyang 23
Kent 22
Lancaster 20
Sindelfingen 18
Singapore 16
Helsinki 15
Haikou 13
Hebei 13
Tianjin 12
Beijing 9
Nanchang 9
Rome 9
Boardman 8
Hangzhou 8
Changsha 6
Jiaxing 6
Ningbo 6
Taiyuan 6
Taizhou 6
Verona 6
Milan 5
Zhengzhou 5
Falls Church 4
Lanzhou 4
Caltanissetta 3
Guangzhou 3
Leawood 3
Nürnberg 3
Qingdao 3
San Mateo 3
Seattle 3
Auburn Hills 2
Bangalore 2
Chicago 2
Edinburgh 2
Ficarazzi 2
Norwalk 2
San Diego 2
Timisoara 2
Washington 2
Ardabil 1
Auckland 1
Augusta 1
Canberra 1
Fairfield 1
Gangdong-gu 1
Mehlingen 1
Monmouth Junction 1
Moscow 1
Oklahoma City 1
Provo 1
Redwood City 1
San Francisco 1
Sofia 1
São Paulo 1
Tokyo 1
Vienna 1
Warsaw 1
Totale 1.389
Nome #
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 125
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 94
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 87
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 87
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 83
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 82
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 80
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 80
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 75
Natural course and prognostic factors of hepatitis B. 74
Natural history of hepatitis B virus infection and disease 72
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 72
Incidenza e fattori di rischio di epatocarcinoma. 71
Natural history of hepatitis B and prognostic factors of disease progression 71
Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C 71
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 71
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 70
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 70
Hepatocellular carcinoma in cirrhosis:incidence and risk factors 69
The risk of hepatocellular carcinoma (HCC) among patients with cirrhosis 67
Storia naturale della epatite cronica e cirrosi da virus C. 66
The risk of hepatocellular carcinoma (HCC) in cirrhosis 60
Efficacy of consensus interferon (CIFN) plus ribavirin (RBV) as initial treatment for chronic hepatitis C patients: an italian multicentre study 59
Totale 1.756
Categoria #
all - tutte 5.212
article - articoli 1.711
book - libri 0
conference - conferenze 2.626
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 875
Totale 10.424


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020204 33 2 0 23 1 18 24 23 7 26 6 41
2020/2021214 14 42 35 15 15 19 0 23 15 0 33 3
2021/2022163 10 43 1 3 26 5 2 10 11 3 8 41
2022/2023448 33 64 40 92 32 98 7 23 42 3 9 5
2023/2024220 8 12 19 44 39 39 4 2 0 2 36 15
2024/202512 12 0 0 0 0 0 0 0 0 0 0 0
Totale 1.756